Skip to main content
Journal cover image

Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.

Publication ,  Journal Article
Swisher, SG; Moughan, J; Komaki, RU; Ajani, JA; Wu, TT; Hofstetter, WL; Konski, AA; Willett, CG
Published in: J Thorac Oncol
February 2017

INTRODUCTION: The impact of selective surgical resection for patients with esophageal cancer treated with definitive chemoradiation has not been clearly evaluated long-term. METHODS: NRG (National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, Gynecologic Oncology Group) Oncology Radiation Therapy Oncology Group 0246 was a multi-institutional, single-arm, open-label, nonrandomized phase II study that enrolled 43 patients from September 2003 to March 2008 with clinical stage T1-4N0-1M0 squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction from 19 sites. Patients received induction chemotherapy with fluorouracil (650 mg/m2/d), cisplatin (15 mg/m2/d), and paclitaxel (200 mg/m2/d) for two cycles followed by concurrent chemoradiation consisting of 50.4 Gy of radiation (1.8 Gy per fraction) and daily fluorouracil (300 mg/m2/d) with cisplatin (15 mg/m2/d) over the first 5 days. After definitive chemoradiation, patients were evaluated for residual disease. Selective esophagectomy was considered only for patients with residual disease after chemoradiation (clinical incomplete response) or recurrent disease on surveillance. RESULTS: This report looks at the long-term outcome of this selective surgical strategy. With a median follow-up of 8.1 years (minimum to maximum for 12 alive patients 7.2-9.8 years), the estimated 5- and 7-year survival rates are 36.6% (95% confidence interval [CI]: 22.3-51.0) and 31.7% (95% CI: 18.3-46.0). Clinical complete response was achieved in 15 patients (37%), with 5- and 7-yearr survival rates of 53.3% (95% CI: 26.3-74.4) and 46.7% (95% CI: 21.2-68.7). Esophageal resection was not required in 20 of 41 patients (49%) on this trial. CONCLUSIONS: The long-term results of NRG Oncology Radiation Therapy Oncology Group 0246 demonstrate promising efficacy of a selective surgical resection strategy and suggest the need for larger randomized studies to further evaluate this organ-preserving approach.

Duke Scholars

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

February 2017

Volume

12

Issue

2

Start / End Page

368 / 374

Location

United States

Related Subject Headings

  • Survival Rate
  • Prognosis
  • Paclitaxel
  • Organ Sparing Treatments
  • Oncology & Carcinogenesis
  • Neoplasm, Residual
  • Neoplasm Staging
  • Induction Chemotherapy
  • Humans
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Swisher, S. G., Moughan, J., Komaki, R. U., Ajani, J. A., Wu, T. T., Hofstetter, W. L., … Willett, C. G. (2017). Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol, 12(2), 368–374. https://doi.org/10.1016/j.jtho.2016.10.002
Swisher, Stephen G., Jennifer Moughan, Ritsuko U. Komaki, Jaffer A. Ajani, Tsung T. Wu, Wayne L. Hofstetter, Andre A. Konski, and Christopher G. Willett. “Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.J Thorac Oncol 12, no. 2 (February 2017): 368–74. https://doi.org/10.1016/j.jtho.2016.10.002.
Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, et al. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol. 2017 Feb;12(2):368–74.
Swisher, Stephen G., et al. “Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.J Thorac Oncol, vol. 12, no. 2, Feb. 2017, pp. 368–74. Pubmed, doi:10.1016/j.jtho.2016.10.002.
Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol. 2017 Feb;12(2):368–374.
Journal cover image

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

February 2017

Volume

12

Issue

2

Start / End Page

368 / 374

Location

United States

Related Subject Headings

  • Survival Rate
  • Prognosis
  • Paclitaxel
  • Organ Sparing Treatments
  • Oncology & Carcinogenesis
  • Neoplasm, Residual
  • Neoplasm Staging
  • Induction Chemotherapy
  • Humans
  • Follow-Up Studies